Evaluating the economic consequences of early antidepressant treatment discontinuation: A comparison between controlled-release and immediate-release paroxetine

Journal of Clinical Psychopharmacology

Volumn 24, Issue 5, 2004, Pages 544-548

  Sheehan, David V ^a   Eaddy, Michael ^b   Sarnes, Matthew ^b   Vishalpura, Tejal ^b   Regan, Timothy ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b XCENDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DEPRESSION; DRUG RELEASE; DRUG WITHDRAWAL; ECONOMIC ASPECT; EVALUATION; FEMALE; HEALTH CARE COST; HOSPITAL CHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; COST SAVINGS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER; DRUG COSTS; FEMALE; HEALTH EXPENDITURES; HOSPITALIZATION; HUMANS; MALE; MANAGED CARE PROGRAMS; MATCHED-PAIR ANALYSIS; MIDDLE AGED; PANIC DISORDER; PATIENT DROPOUTS; PHOBIC DISORDERS; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 4644280497     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000140999.45053.07     Document Type: Article

References (20)

1. National Committee for Quality Assurance (NCQA). The State of Health Care Quality in 2003. Washington, DC: NCQA; 2003.
2. Sood N, Treglia M, Obenchain RL, et al. Determinant of antidepressant treatment outcome. Am J Manag Care. 2000;6:1327-1336.
3. Thompson D, Buesching D, Gregor KJ, et al. Patterns of antidepressant use and their relation to costs of care. Am J Manag Care. 1996;2:1239-1246.
4. American Psychiatric Association (APA). Practice guideline of patients with major depressive disorder (revision). Am J Psychiatry. 2000;157(suppl 4):1-45.
5. Bull SA, Hunkeler EM, Lee JY, et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother. 2002;36:578-584.
6. Isaacsohn JL, LaSalle J, Chao G, et al. Comparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-release 40-mg capsules in patients with primary hypercholesterolemia. Clin Ther. 2003;25(3):904-918.
7. Tangeman HJ, Patterson JH. Extended-release metoprolol succinate in chronic heart failure. Ann Pharmacother. 2003;37(5):701-710.
8. Michel MC. A benefit-risk assessment of extended-release oxybutynin. Drug Safety. 2002;25(12):867-876.
9. van Kerrebroeck P, Jardin A, Lavai KU, et al. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol. 2000;37(3):306-313.
10. Golden RN, Nemeroff ACB, McSorley P, et al. Efficacy and tolerance of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry. 2002;63:577-588.
11. Keller MB. Paroxetine treatment of major depressive disorder. Psychopharmacol Bull. 2003;37(suppl 1):42-52.
12. Golden RN. Efficacy and tolerability of controlled-release paroxetine. Psychopharmacol Bull. 2003;37(suppl 1):176-186.
13. Eaddy ME, Bramley TJ, Regan T. Time to antidepressant discontinuation: a comparison of controlled-release paroxetine and immediate-release selective serotonin reuptake inhibitors. Manag Care Interface. 2003;16(12):22-27.
14. Pharmetrics Integrated Outcomes Database. Watertown, MA: Pharmetrics, 2003. Updated September 2003.
15. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
16. Deyo RA, Gherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
17. Siegmund KD, Todorov AA, Province MA. A frailty approach for modeling diseases with variable age of onset in families: the NHLBI family heart study. Stat Med. 1999;18:1517-1528.
18. Etzioni RD, Feuer EJ, Sullivan SD, et al. On the use of survival techniques to estimate medical care costs. J Health Econ. 1999;18:365-380.
19. Manning W. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ. 1998;17:283-295.
20. Lin EH, VonKorff M, Katon W, et al. The role of the primary care physician in patient's adherence to antidepressant therapy. Med Care. 1995;33:67-74.